论文部分内容阅读
目的:探讨铁调素对维持性血液透析(MHD)患者铁稳态的影响。方法:将62例MHD患者作为观察组,将30例健康志愿者作为对照组,分别检测比较两组铁代谢综合指标,包括血清铁、铁蛋白、转铁蛋白饱和度、总铁结合力及血红蛋白,应用酶联免疫吸附法(ELISA)测定两组铁调素水平。结果:观察组铁调素水平与对照组比较差异有统计学意义(P<0.01),血清铁调素与铁蛋白、高敏C反应蛋白呈正相关(r分别为0.525、0.285,P<0.05),与血红蛋白、总铁结合力、肾小球滤过率呈负相关(r分别为-0.542、-0.265、-0.543,P<0.05)。结论:铁调素参与MHD患者铁代谢及红细胞生成的调控,清除铁调素有利于恢复机体铁稳态的纠正贫血。
Objective: To investigate the effect of hepcidin on iron homeostasis in patients with maintenance hemodialysis (MHD). Methods: Totally 62 patients with MHD were selected as observation group and 30 healthy volunteers as control group. The comprehensive indexes of iron metabolism, including serum iron, ferritin, transferrin saturation, total iron binding capacity and hemoglobin , And the level of hepcidin in the two groups was measured by enzyme-linked immunosorbent assay (ELISA). Results: The level of hepcidin in the observation group was significantly different from that in the control group (P <0.01). Serum hepcidin was positively correlated with ferritin and high-sensitivity C-reactive protein (r = 0.525,0.285, P <0.05) And hemoglobin, total iron binding capacity, glomerular filtration rate was negatively correlated (r = -0.542, -0.265, -0.543, P <0.05). CONCLUSION: Hepcidin is involved in the regulation of iron metabolism and erythropoiesis in patients with MHD, and the removal of hepcidin helps to restore the body’s iron homeostasis and correct anemia.